NCT01001260

PGD2 Formation in Vascular Injury

Biosynthesis of PGD2 in Vascular Injury

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 51 (actual)
• Sponsor: University of Pennsylvania · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

To investigate the biosynthesis of PGD2 during percutaneous transluminal coronary angioplasty (PTCA) procedure.

Detailed description

A) To determine whether biosynthesis of PGD2 is altered in response to vascular injury in humans B) Patients will be grouped base on their aspirin using status. Three groups of no aspirin but an alternative anti-platelet medicine, low dose (81 mg) aspirin, high dose 325 mg aspirin will be enrolled.

Conditions

• Coronary Artery Disease
• Acute Coronary Syndrome
• Stable Angina

Interventions

Type	Name	Description
DRUG	No ASA	Alternative antiplatelet therapy instead of aspirin
DRUG	Low dose ASA	Low dose aspirin (81mg) prior to PTCA
DRUG	325 mg ASA	high dose of aspirin prior to PTCA

Timeline

• Start date: 2007-08-01
• Primary completion: 2011-02-01
• Completion: 2012-01-01
• First posted: 2009-10-26
• Last updated: 2019-06-11